311 related articles for article (PubMed ID: 22297638)
21. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
[TBL] [Abstract][Full Text] [Related]
22. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical assessment of mitotic count in uveal melanoma.
Angi M; Damato B; Kalirai H; Dodson A; Taktak A; Coupland SE
Acta Ophthalmol; 2011 Mar; 89(2):e155-60. PubMed ID: 19900200
[TBL] [Abstract][Full Text] [Related]
24. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in head and neck mucosal malignant melanoma.
Çomoğlu Ş; Polat B; Çelik M; Şahin B; Enver N; Keleş MN; Sarı ŞÖ
Auris Nasus Larynx; 2018 Feb; 45(1):135-142. PubMed ID: 28385366
[TBL] [Abstract][Full Text] [Related]
26. Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).
Idriss MH; Kazlouskaya V; Malhotra S; Andres C; Elston DM
J Cutan Pathol; 2013 Jun; 40(6):557-63. PubMed ID: 23550775
[TBL] [Abstract][Full Text] [Related]
27. Validation of mitosis counting by automated phosphohistone H3 (PHH3) digital image analysis in a breast carcinoma tissue microarray.
Dessauvagie BF; Thomas C; Robinson C; Frost FA; Harvey J; Sterrett GF
Pathology; 2015 Jun; 47(4):329-34. PubMed ID: 25938351
[TBL] [Abstract][Full Text] [Related]
28. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
29. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
30. Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients.
Ponti G; Pollio A; Cesinaro AM; Pellacani G; Magnoni C; Seidenari S
Cancer Epidemiol; 2012 Jun; 36(3):303-5. PubMed ID: 22153914
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
Kim YJ; Ketter R; Steudel WI; Feiden W
Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
[TBL] [Abstract][Full Text] [Related]
32. Does mitosis-specific marker phosphohistone H3 help the grading of upper tract urothelial carcinomas in cell blocks?
Solomides CC; Birbe RC; Nicolaou N; Bagley D; Bibbo M
Acta Cytol; 2012; 56(3):285-8. PubMed ID: 22555531
[TBL] [Abstract][Full Text] [Related]
33. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.
Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN
Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
35. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker.
Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D
Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532
[TBL] [Abstract][Full Text] [Related]
36. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
37. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study.
Veras E; Malpica A; Deavers MT; Silva EG
Int J Gynecol Pathol; 2009 Jul; 28(4):316-21. PubMed ID: 19483635
[TBL] [Abstract][Full Text] [Related]
38. Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine Tumors.
Kim MJ; Kwon MJ; Kang HS; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Park HC
Biomed Res Int; 2018; 2018():1013640. PubMed ID: 29780816
[TBL] [Abstract][Full Text] [Related]
39. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
40. Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency.
Laflamme P; Mansoori BK; Sazanova O; Orain M; Couture C; Simard S; Trahan S; Manem V; Joubert P
Hum Pathol; 2020 Dec; 106():74-81. PubMed ID: 33007357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
